Internal Medicine, Hematology & Oncology · Grand Rapids, MI
NPI
1972705838
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
145 Michigan St NE Ste 3100
Grand Rapids, MI, 49503
Phone (616) 954-9800
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.0M
112,275 services
Medicare patients, 2024
331
Average age 71
Drug cost, 2024
$1.8M
1,049 prescriptions
Company payments, 2025
$25K
From 34 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sreenivasa Chandana was code J9263 (injection, oxaliplatin, 0.5 mg), 21,700 times for 14 patients. In total Sreenivasa Chandana billed 112,275 services in 190 codes, and Medicare paid $2.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-03-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 21,700 | 14 | $0.06 | $1,203 |
| J1930 Injection, lanreotide, 1 mg | Office | 7,920 | 15 | $38.50 | $305K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,372 | 61 | $0.09 | $210 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,050 | 36 | $0.71 | $748 |
| 36415 Venipuncture Blood Collection | Office | 699 | 143 | $8.65 | $6,046 |
| 85025 Blood Count | Office | 674 | 139 | $7.61 | $5,129 |
| J9190 Injection, fluorouracil, 500 mg | Office | 640 | 13 | $2.34 | $1,496 |
| 80053 Clinical Chemistry | Office | 622 | 138 | $10.35 | $6,438 |
| 96375 Injection Administration | Office | 450 | 75 | $10.73 | $4,829 |
| J3480 Injection, potassium chloride, per 2 meq | Office | 430 | 14 | $0.09 | $36.98 |
| 96413 Chemotherapy Administration | Office | 404 | 100 | $89.07 | $36K |
| 99214 Office E&M - Established | Office | 291 | 123 | $95.75 | $28K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 270 | 12 | $0.23 | $63.39 |
| 96417 Chemotherapy Administration | Office | 184 | 32 | $45.93 | $8,451 |
| 83735 Clinical Chemistry | Office | 158 | 33 | $6.57 | $1,038 |
By year: 2022 $2.2M for 134,138 services; 2023 $2.1M for 104,190 services; 2024 $2.0M for 112,275 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 699 | 143 | $8.65 | $6,046 |
| 85025 Blood Count | 674 | 139 | $7.61 | $5,129 |
| 80053 Clinical Chemistry | 622 | 138 | $10.35 | $6,438 |
| 83735 Clinical Chemistry | 158 | 33 | $6.57 | $1,038 |
| 86301 Immunoassay | 113 | 29 | $20.39 | $2,304 |
| 84443 Clinical Chemistry | 85 | 26 | $16.46 | $1,399 |
| 82378 Clinical Chemistry | 60 | 29 | $18.58 | $1,115 |
| 81000 Clinical Chemistry | 54 | 15 | $3.94 | $213 |
| 84156 Clinical Chemistry | 54 | 12 | $3.60 | $194 |
| 84100 Clinical Chemistry | 50 | 17 | $4.65 | $233 |
Medicare prescription drug claims, 2024
In 2024, the drug Sreenivasa Chandana prescribed most often to Medicare patients was Prochlorperazine Maleate, with 143 prescriptions and refills. In total Sreenivasa Chandana wrote 1,049 Medicare prescriptions that cost $1.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prochlorperazine Maleate Generic | 143 | 143 | 108 | $1,950 |
| Creon Lipase/Protease/Amylase | 71 | 95 | 21 | $254K |
| Prednisone Generic | 63 | 65 | 24 | $185 |
| Olanzapine Generic | 54 | 56 | 20 | $221 |
| Eliquis Apixaban | 49 | 59 | 12 | $33K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 35 | 35 | 30 | $341 |
| Potassium Chloride Generic | 33 | 36 | 19 | $832 |
| Ondansetron Odt Ondansetron | 26 | 26 | 17 | $307 |
| Nyvepria Pegfilgrastim-Apgf | 23 | 23 | Under 11 | $115K |
| Dexamethasone Generic | 22 | 22 | Under 11 | $313 |
| Lidocaine Hcl Viscous Lidocaine Hcl | 21 | 21 | Under 11 | $341 |
| Levothyroxine Sodium Generic | 19 | 20 | Under 11 | $99.69 |
| Furosemide Generic | 19 | 19 | 16 | $34.33 |
| Jakafi Ruxolitinib Phosphate | 18 | 18 | Under 11 | $271K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 17 | 17 | 13 | $360 |
Brand drugs: - claims; generic drugs: 784 claims; opioid claims: 45.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sreenivasa Chandana $25K ($25K in general payments such as food, travel and fees and $93 for research) from 34 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $6,883.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 14 | $6,883 |
| Corcept Therapeutics CORT | 7 | $3,666 |
| Jazz Pharmaceuticals Inc. JAZZ | 2 | $3,317 |
| Immunocore Limited IMCR | 2 | $2,431 |
| Eisai Inc. 4523.T | 2 | $2,416 |
| BeOne Medicines USA, Inc. ONC | 1 | $1,950 |
| Incyte Corporation INCY | 3 | $1,477 |
| Novocure Inc. NVCR | 9 | $1,372 |
| E.R. Squibb & Sons, L.L.C. BMY | 10 | $242 |
| Merck Sharp & Dohme LLC MRK | 5 | $161 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.